Anti-Human HLA-DP (MHC Class II) Monomorphic - Purified in vivo GOLD™ Functional Grade
| Code | Size | Price |
|---|
| LEI-H260-1.0mg | 1.0 mg | £175.00 |
Quantity:
| LEI-H260-5.0mg | 5.0 mg | £380.00 |
Quantity:
| LEI-H260-25mg | 25 mg | £974.00 |
Quantity:
| LEI-H260-50mg | 50 mg | £1,516.00 |
Quantity:
| LEI-H260-100mg | 100 mg | £2,159.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG3
Antibody Clonality: Monoclonal
Antibody Clone: B7/21
Regulatory Status: RUO
Target Species: Human
Applications:
- Flow Cytometry
- Immunocytochemistry (ICC)
- In Vivo Assay
Shipping:
2-8°C
Storage:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Note: This antibody is prone to precipitation at 2-8°C resulting in a slight opaque white liquid. At room temperature liquid is clear and colorless.
Further Information
Antigen Distribution:
HLA-DP is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
in vivo GOLD™, Purified in vivo Functional Grade
Format:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Unknown
Long Description:
HLA-DP antibody, clone B7/21, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DP isotype (HLA-DP). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation1. HLA-DP consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain2 encoded by the HLA-DPA1 and HLA-DPB1 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens3. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling4. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation5 and can transduce signals into T cells, enhancing T cell proliferation and activity6. High HLA-DP expression is associated with an increased risk of graft-versus-host disease7. Specific alleles of HLA-DP are associated with autoimmune diseases, including rheumatoid arthritis8.
Purity:
?95% monomer by analytical SEC, >95% by SDS Page
Target:
HLA-DP Monomorphic
References
1. Holling TM, et al. (2004) Hum Immunol. 65(4):282-90.
2. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):10618-25.
3. Wieczorek M, et al. (2017) Front Immunol. 8:292.
4. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921.
5. Barnaba V, et al. (1994) Eur J Immunol. 24(1):71-5.
6. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60.
7. Petersdorf EW, et al. (2015) N Engl J Med. 373(7):599-609.
8. Raychaudhuri S, et al. (2012) Nat Genet. 44(3):291-6.
Related Products
| Product Name | Product Code | Supplier | Anti-Human HLA A2,B7 (MHC Class I) - Purified in vivo GOLD™ Functional Grade | LEI-H1685 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human HLA-DR (MHC Class II) - Purified in vivo GOLD™ Functional Grade | LEI-H261 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human HLA-DQ (MHC Class II) - Purified in vivo GOLD™ Functional Grade | LEI-H262 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human HLA-A, B, C (MHC Class I) - Purified in vivo GOLD™ Functional Grade | LEI-H263 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||